Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Thursday, May 1, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences has announced multiple presentations regarding its in vivo gene editing programs at the ASGCT Annual Meeting. The company is leveraging its proprietary ARCUS platform to develop therapies focused on gene elimination, insertion, and excision. This participation highlights the company's commitment to advancing gene editing technologies.
Price reaction · baseline $5.64 (2025-04-30 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is actively presenting at a major conference.
  • The company is advancing its in vivo gene editing programs.
  • Utilization of the proprietary ARCUS platform indicates innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–May 1, 2025– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today

Frequently Asked Questions

What is the focus of Precision BioSciences' presentations?

The presentations focus on in vivo gene editing programs utilizing the ARCUS platform.

Where will the presentations take place?

The presentations will be held at the American Society of Gene and Cell Therapy Annual Meeting.

What technologies does Precision BioSciences use?

The company uses its proprietary ARCUS platform for gene editing therapies.

What types of gene editing does Precision BioSciences develop?

They develop therapies for gene elimination, insertion, and excision.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences ASGCT gene editing ARCUS platform in vivo therapies
Last updated: May 1, 2025

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →